PATENT CLAIM ANALYSIS

Application Number: 16021089
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "159000"]

Abstract:
A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.

Claim (Index 17):
The liquid pharmaceutical suspension of  claim 16  wherein the buffer is selected from the group consisting of acetic acid, sodium acetate, citric acid, sodium citrate, monobasic sodium phosphate, dibasic sodium phosphate, sodium carbonate, sodium bicarbonate, succinic acid, sodium succinate, potassium dihydrogen phosphate, phosphoric acid, salicylic acid, and combinations thereof.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.54839
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15289445', '14698934', '16021502', '14698962', '15289470']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8101129708433618
- 35 USC 102 Novelty (BERT): 0.5202957581464981
- Combined Prediction Score: 0.7811312495736754
- Mean Citation Score: 267.290702
- Max Citation Score: 324.75854
- Similarity Product: 237.2309395448005

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test